424 related articles for article (PubMed ID: 30761135)
1. Autoantibodies Against C3b-Functional Consequences and Disease Relevance.
Vasilev VV; Radanova M; Lazarov VJ; Dragon-Durey MA; Fremeaux-Bacchi V; Roumenina LT
Front Immunol; 2019; 10():64. PubMed ID: 30761135
[TBL] [Abstract][Full Text] [Related]
2. Detection of Anti-C3b Autoantibodies by ELISA.
Radanova M; Roumenina LT; Vasilev V
Methods Mol Biol; 2021; 2227():133-139. PubMed ID: 33847938
[TBL] [Abstract][Full Text] [Related]
3. Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function.
Nilsson B; Ekdahl KN; Svarvare M; Bjelle A; Nilsson UR
Clin Exp Immunol; 1990 Nov; 82(2):262-7. PubMed ID: 2146995
[TBL] [Abstract][Full Text] [Related]
4. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
5. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
[TBL] [Abstract][Full Text] [Related]
6. Activation of the alternative complement pathway.
Fearon DT
CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
[No Abstract] [Full Text] [Related]
7. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
8. Circulating anti-C3b IgG in lupus nephritis: A large cohort study.
Tao J; Song D; Liu XL; Yu F; Zhao MH
Clin Immunol; 2020 Aug; 217():108514. PubMed ID: 32565324
[TBL] [Abstract][Full Text] [Related]
9. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B.
Becherer JD; Alsenz J; Esparza I; Hack CE; Lambris JD
Biochemistry; 1992 Feb; 31(6):1787-94. PubMed ID: 1371073
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
Garred P; Mollnes TE; Lea T; Fischer E
Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
[TBL] [Abstract][Full Text] [Related]
11. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
12. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Corvillo F; Okrój M; Nozal P; Melgosa M; Sánchez-Corral P; López-Trascasa M
Front Immunol; 2019; 10():886. PubMed ID: 31068950
[TBL] [Abstract][Full Text] [Related]
13. Activated C3 (C3b) in the nephritic glomerulus.
Pan C; Strife CF; McAdams AJ; West CD
Pediatr Nephrol; 1993 Aug; 7(4):379-86. PubMed ID: 8398646
[TBL] [Abstract][Full Text] [Related]
14. A new enzyme-linked immunosorbent assay (ELISA) for measuring immunoconglutinins directed against the third component of human complement. Findings in systemic lupus erythematosus.
Durand CG; Burge JJ
J Immunol Methods; 1984 Oct; 73(1):57-66. PubMed ID: 6491304
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
Tanuma Y; Ohi H; Hatano M
Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
[TBL] [Abstract][Full Text] [Related]
16. A C3 convertase assay for nephritic factor functional activity.
Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
[TBL] [Abstract][Full Text] [Related]
17. Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.
Birmingham DJ; Bitter JE; Ndukwe EG; Dials S; Gullo TR; Conroy S; Nagaraja HN; Rovin BH; Hebert LA
Clin J Am Soc Nephrol; 2016 Jan; 11(1):47-53. PubMed ID: 26700439
[TBL] [Abstract][Full Text] [Related]
18. Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis.
Vasilev VV; Noe R; Dragon-Durey MA; Chauvet S; Lazarov VJ; Deliyska BP; Fremeaux-Bacchi V; Dimitrov JD; Roumenina LT
J Biol Chem; 2015 Oct; 290(42):25343-55. PubMed ID: 26245903
[TBL] [Abstract][Full Text] [Related]
19. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.
Marinozzi MC; Roumenina LT; Chauvet S; Hertig A; Bertrand D; Olagne J; Frimat M; Ulinski T; Deschênes G; Burtey S; Delahousse M; Moulin B; Legendre C; Frémeaux-Bacchi V; Le Quintrec M
J Am Soc Nephrol; 2017 May; 28(5):1603-1613. PubMed ID: 28096309
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
